TITLE:
Safety and Antiviral Study of ACH126, 433 (b-L-Fd4C) in Adults With Lamivudine-resistant Chronic Hepatitis B

CONDITION:
Chronic Hepatitis B

INTERVENTION:
ACH126, 433 (b-L-Fd4C)

SUMMARY:

      The purpose of this study is to determine the safety and antiviral HBV activity of ACH126,
      433 (b-L-Fd4C) in the treatment of adults with lamivudine-resistant chronic Hepatitis B.
    

DETAILED DESCRIPTION:

      Evaluation of safety and antiviral activity of 3 dose levels of ACH126, 443 over a twelve
      week treatment in the population described.
    

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria

          -  Adults  18 years of age

          -  Chronic HBV infection, known to be HbsAg positive  6 months

          -  On lamivudine, either 100 or 150 mg daily for the treatment of chronic hepatitis B
             infection and

          -  Exhibit a 2-3 log decrease in HBV DNA levels followed by a rebound of at least 1.5
             log HBV DNA or

               -  Achieved an HBV DNA level of <10,000 copies/mL HBV DNA on at least 2 occasions
                  and have rebounded to > 100,000 copies/mL HBV DNA, or

               -  Have a demonstrable 3TC resistant genotype regardless of treatment history.

          -  HBeAG positive

          -  HIV negative

          -  Serum ALT 1.5 and 10x times upper limit of normal

          -  HGB 10g/dl or HCT 30% (in the absence of blood transfusions or erythropoietin
             treatment in the preceding two weeks)

          -  Platelet count >75,000/mm(^3), (in the absence of ongoing G-CSF therapy)

          -  Serum creatinine <1.1 times upper limit of normal (ULN)

          -  Negative radiologic screening test (ultrasound, CT scan or MRI) for hepatocellular
             carcinoma (HCC) within 6 months prior to entry

          -  PT/INR<2

          -  Subjects of reproductive capability must utilize an approved forms of birth control

          -  All women of child-bearing capability must have a negative serum or urine pregnancy
             test (minimum sensitivity of 24 IU/L of b-HCG) within 72 hours prior to the start of
             study medication

          -  Subjects must be able to provide written informed consent

          -  Subject must be available for follow-up for a period of 20 weeks

        Exclusion Criteria

          -  HIV infection

          -  Hepatitis C co-infection

          -  Alcohol abuse

          -  Pregnancy or breast-feeding

          -  Inability to tolerate oral medication

          -  Any clinical condition or prior therapy that, in the Investigator's opinion, would
             make the subject unsuitable for the study or unable to comply with the dosing
             requirements

          -  Use of any investigational drug

          -  Patients with decompensated liver disease

          -  Use of any concomitant herbal treatments
      
